The UK and US have reached a important commercial pact that will keep no import taxes on UK drug shipments going into the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This move guarantees that import taxes on these crucial goods will stay at nothing for a timeframe of three years.
This agreement comes after recent threats to hike duties on patented drug imports, with potential rates mentioned as high as one hundred percent.
"This arrangement between the United Kingdom strengthens the global environment for new treatments and introduces much-needed balance to American-British pharmaceutical trade," a statement noted.
Economic Impact
Drugs represent one of the UK's largest goods shipped to the America, which is by far the largest destination for major UK drugmakers.
Export figures indicate that in the one-year period prior to last September, the UK sold medicines worth over eleven billion pounds to the US. This amount made up a significant portion of British export trade in that span.
"This agreement protects jobs, boosts funding and paves the way for the UK to become a global hub for biotech and pharma," a minister remarked.
Specific UK Commitments
The deal includes several key commitments from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise overall public funding on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be restricted at 15%. Previously, rebates were more than 20%.
Industry Background
This agreement follows a protracted row between the sector and the UK government over medicine costs and NHS adoption.
These tensions were heightened by claims that American patients were charged several times more for the same drugs than people in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been halted or scrapped, while major investments have been announced toward US facilities.
One official publicly accepted that the NHS must invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the last ten years.
